Phase 1 clinical study of highly purified natural killer (NK) cell infusion for patients with refractory digestive/gastrointestinal cancer to standard therapy
Latest Information Update: 12 May 2016
At a glance
- Drugs Natural killer cell therapy-Takara-Bio (Primary)
- Indications Gastrointestinal cancer
- Focus Adverse reactions
- Sponsors Takara Bio
Most Recent Events
- 13 May 2014 New trial record
- 09 Apr 2014 Status changed from active, no longer recruiting to completed, based on reported results.
- 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR-2014).